Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,281
  • Shares Outstanding, K 4,045
  • Annual Sales, $ 29,620 K
  • Annual Income, $ -47,580 K
  • EBIT $ -124 M
  • EBITDA $ -123 M
  • 60-Month Beta 0.77
  • Price/Sales 4.73
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.99
  • Most Recent Earnings $-1.61 on 11/10/25
  • Next Earnings Date 03/16/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.89
  • Number of Estimates 2
  • High Estimate -2.95
  • Low Estimate -4.82
  • Prior Year -2.00
  • Growth Rate Est. (year over year) -94.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.30 +16.99%
on 12/18/25
10.47 -7.26%
on 12/16/25
+1.29 (+15.32%)
since 12/05/25
3-Month
7.99 +21.53%
on 12/04/25
11.65 -16.65%
on 10/22/25
-1.36 (-12.29%)
since 10/07/25
52-Week
4.85 +100.21%
on 06/30/25
21.94 -55.74%
on 02/20/25
-5.90 (-37.80%)
since 01/07/25

Most Recent Stories

More News
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum 

Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare disease Kyntra Bio will begin trading on Nasdaq...

FGEN : 9.71 (+7.65%)
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of...

FGEN : 9.71 (+7.65%)
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being...

FGEN : 9.71 (+7.65%)
FibroGen: Q3 Earnings Snapshot

FibroGen: Q3 Earnings Snapshot

FGEN : 9.71 (+7.65%)
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

Completed the sale of FibroGen China to AstraZeneca for approximately $220 million Initiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting...

FGEN : 9.71 (+7.65%)
FibroGen to Report Third Quarter 2025 Financial Results

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct...

FGEN : 9.71 (+7.65%)
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy...

FGEN : 9.71 (+7.65%)
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance Successfully repaid term loan to Morgan Stanley Tactical...

FGEN : 9.71 (+7.65%)
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27 th  Annual Global Investment...

FGEN : 9.71 (+7.65%)
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for...

FGEN : 9.71 (+7.65%)

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 10.42
2nd Resistance Point 10.08
1st Resistance Point 9.90
Last Price 9.71
1st Support Level 9.38
2nd Support Level 9.04
3rd Support Level 8.86

See More

52-Week High 21.94
Fibonacci 61.8% 15.41
Fibonacci 50% 13.39
Fibonacci 38.2% 11.38
Last Price 9.71
52-Week Low 4.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar